Reconfiguring social value in health research through the lens of liminality

Bioethics

Volumn 31, Issue 2, 2017, Pages 87-96

  Ganguli Mitra, Agomoni ^a   Dove, Edward S ^a   Laurie, Graeme T ^a   Taylor Alexander, Samuel ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Bioethics; Health research; Liminality; Social value

Indexed keywords

BIOETHICS; HUMAN; MEDICAL RESEARCH; RELIGION; RESEARCH ETHICS; SOCIAL PSYCHOLOGY;

BIOETHICS; ETHICS, RESEARCH; HUMANS; RELIGION AND PSYCHOLOGY; SOCIAL VALUES; SPIRITUALITY;

EID: 85009084581     PISSN: 02699702     EISSN: 14678519     Source Type: Journal    
DOI: 10.1111/bioe.12324     Document Type: Note

References (48)

1. The Nuremberg Code, n.d. Available at: http://www.hhs.gov/ohrp/ archive/nurcode.html [Accessed 11 Apr 2016].
2. M. Habets, J. J.M. van Delden & A.L. Bredenoord. The Social Value of Clinical Research. BMC Med Ethics 2014; 15: 66
3. A. Rid & D. Wendler. A Framework for Risk-Benefit Evaluations in Biomedical Research. Kennedy Inst Ethics J 2011; 21: 141–179.
4. Department of Health (UK). Governance arrangements for research ethics committees: A harmonised edition 2011 (updated April 2012) para. 3.2.2. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213753/dh_133993.pdfhttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213753/dh_ 133993.pdf [Accessed 11Apr 2016].
5. Ibid: at para. 3.2.3.
6. CIOMS. Final Draft CIOMS Guidelines. 2015. Available at: http://www.cioms.ch/final_draft_CIOMS_guidelines-10_september_2015- WITH_WATERMARKS.pdf [Accessed 10 Sep 2016].
7. Habets, van Delden, and Bredenoord, op. cit. note 2.
8. Ibid.
9. A. Wertheimer. The Social Value Requirement Reconsidered: The Social Value Requirement Reconsidered. Bioethics 2015; 29: 301–308.
10. Council for International Organizations of Medical Sciences and World Health Organization (CIOMS). 2002. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva: CIOMS; Sec. 8. Available at: http://www.cioms.ch/publications/guidelines/ guidelines_nov_2002_blurb.htm [Accessed 10 Sep 2016].
11. E.J. Emanuel, D. Wendler & C. Grady. 2008. An Ethical Framework for Biomedical Ethics. In The Oxford Textbook of Clinical Research Ethics, E.J. Emanuel et.al., eds. Oxford and New York: Oxford University Press: 127.
12. D. M. Wenner. The Social Value of Knowledge and International Clinical Research. DevWorld Bioeth 2015; 15:76–84.
13. Wertheimer, op. cit. note 8, p. 302.
14. Emanuel et al. op. cit. note 16, p. 127;
15. A. London. A Non- Paternalistic Model of Research Oversight: Assessing the Benefits of Prospective Review. J Law Med Ethics 2012; 40: 942.
16. Wertheimer, op. cit. note 8, p. 302.
17. CIOMS, op. cit. note 5.
18. A. Van Gennep. 1960. The Rites of Passage. Chicago: University of Chicago Press
19. B. Thomassen. 2014. Liminality and The Modern: Living Through the In-Between. Farnham: Ashgate.
20. Van Gennep, op. cit. note 16, p. 21.
21. B. Thomassen. 2014. Liminality and The Modern: Living Through the In-Between. Farnham: Ashgate; A. Horvath, B. Thomassen& H.Wydra, eds. 2015. Breaking Boundaries: Varieties of Liminality. Oxford/New York: Berghahn Books.
22. K. Knorr Cetina. 2009. Epistemic Cultures: How the Sciences Make Knowledge. Cambridge, MA: Harvard University Press. See also H-J Rheinberger. 1997. Toward a History of Epistemic Things. Synthesizing Proteins in the Test Tube. Stanford, CA: Stanford University Press.
23. Emanuel et al., op. cit. note 10.
24. Emanuel et al., op. cit. note 10.
25. M-P. Kieny. 2016. WHO Research and Development on Zika: Commentary. Available at: http://www.who.int/mediacentre/commentaries/ zika-research-development/en/ [Accessed 10 Sep 2016].
26. Rid &Wendler, op. cit. note 2.
27. Ibid.
28. Ibid.
29. P. Calain. The Ebola Clinical Trials: a precedent for research ethics in disasters. J Med Ethics 2016: 0:1–6
30. WHO, op. cit. note 22. p. 2
31. Ibid 29 Calain, op. cit. note 27.
32. WHO, op cit. note 22. P. 3
33. L. Eckenwiler, J. Pringle, R. Boulanger, and M. Hunt, ‘Real-time Responsiveness for Ethics Oversight During Disaster Research’, 29:9 Bioethics (2015), p. 654.
34. A.H. Kelly & P.W. Geissler. The Value of Transnational Medical Research.” J Cult Econ 2011; 4: 3–10.
35. Ibid.
36. CIOMS, op. cit. note 3, Guideline 1.
37. M. Habets et al. op. cit. note 2, p. 6.
38. A. Rid & D. Wendler. op. cit. note 2, p. 144.
39. A. London, op. cit. note 13, p. 942.
40. G. Laurie. Reflexive governance in biobanking: on the value of policy led approaches and the need to recognise the limits of law. Hum Genet (2011) 130: 347. doi:10.1007/s00439-011-1066-x.
41. G. Laurie, K. Hunter, S. Cunningham-Burley. Guthrie Cards in Scotland: Ethical, Legal and Social Issues. Report, Scottish Government Social Research. 2013; 4.
42. M. Huckaby Lewis. Lessons from the Residual Newborn Screening Dried Blood Sample Litigation. J Law Med Ethics 2015; 43: 32–35.
43. B. Latour. 2005. Reassembling the Social: An Introduction to Actor- Network-Theory. Oxford and New York: Oxford University Press: 1 (emphasis in original).
44. J.H. Jones. 2008. The Tuskegee Syphilis Experiment. In The Oxford Textbook of Clinical Research Ethics, E.J Emanuel et al., eds. Oxford and NewYork: Oxford University Press: 90–93.
45. E.J. Emanuel, D. Wendler, J. Killen, C. Grady. What Makes Clinical Research in Developing Countries Ethical? The Benchmarks of Ethical Research. J Infect Dis 2004; 189(5): 930–937.
46. K. Saha & J.B. Hurlbut. Research Ethics: Treat Donors as Partners in BiobankResearch. Nature 2011; 478: 312–313.
47. L. Rajmil, L. Perestelo-P’erez & M. Herdman. Quality of Life and Rare Diseases. Adv Exp Med Biol, 2010; 686: 251–272.
48. This observation is based on one of the author’s (in preparation) sociotechnical history of theUKCystic Fibrosis Gene Therapy Consortium.